Search

Your search keyword '"Overvad, Thure Filskov"' showing total 202 results
Start Over Author "Overvad, Thure Filskov"
202 results on '"Overvad, Thure Filskov"'

5. Electrocardiographic P terminal force in lead V1, its components, and the association with stroke and atrial fibrillation or flutter

Author

Wolder, Lecia Dixen, Graff, Claus, Baadsgaard, Kirstine H., Langgaard, Monica Lykke, Polcwiartek, Christoffer, Ji-Young Lee, Christina, Skov, Morten Wagner, Torp-Pedersen, Christian, Friedman, Daniel J., Atwater, Brett, Overvad, Thure Filskov, Nielsen, Jonas Bille, Hansen, Steen Moeller, Sogaard, Peter, and Kragholm, Kristian H.

Published
2023
Full Text
View/download PDF

18. Risk of Cerebrovascular Events in Intracerebral Hemorrhage Survivors With Atrial Fibrillation: A Nationwide Cohort Study

Author

Nielsen, Peter Brønnum, primary, Melgaard, Line, additional, Overvad, Thure Filskov, additional, Jensen, Martin, additional, Larsen, Torben Bjerregaard, additional, Lip, Gregory Y.H., additional, Veltkamp, Roland, additional, Harvey, Kirsten H, additional, Korompoki, Eleni, additional, D’Anna, Lucio, additional, Halse, Omid, additional, Hügen, Klemens, additional, Malzahn, Uwe, additional, Ullmann, Sabine, additional, Schuhmann, Carolin, additional, Todd, Gabriele Putz, additional, Brinz, Hannes, additional, Heuschmann, Peter U., additional, Haas, Kirsten, additional, Rücker, Viktoria, additional, Enzinger, Christian, additional, Ropele, Stefan, additional, Pinter, Daniela, additional, Haidegger, Melanie, additional, Gattringer, Thomas, additional, Fandler-Höfler, Simon, additional, Wolfe, Charles D. A., additional, Wang, Yanzhong, additional, Wafa, Hatem A., additional, Montaner, Joan, additional, Palà, Elena, additional, Debette, Stéphanie, additional, Sibon, Igor, additional, Renou, Pauline, additional, Lachaize, Morgane, additional, Milan, Léa, additional, Heyvang, Nathalie, additional, Ledure, Sylvain, additional, Michel, Pascale, additional, Graziani, Mara, additional, Marchini, Laura, additional, Caso, Valeria, additional, Horstmann, Solveigh, additional, Purrucker, Jan, additional, Ringleb, Peter, additional, Haffa, Mariam, additional, Hoppe-Tichy, Torsten, additional, Haefeli, Walter E., additional, Seidling, Hanna M., additional, Burhenne, Jürgen, additional, Foerster, Kathrin I., additional, Lane, Deirdre A, additional, Ivany, Elena, additional, and Lotto, Robyn, additional

Published
2022
Full Text
View/download PDF

21. Positive Predictive Value of Non-Traumatic Bleeding Diagnoses in the Danish National Patient Register.

Author

Thaarup, Maja, Nielsen, Peter Brønnum, Olesen, Anne Estrup, Poulsen, Maria Bitsch, Larsen, Torben Bjerregaard, Wittström, Felix, and Overvad, Thure Filskov

Subjects
ELECTRONIC health records, DIAGNOSIS, NOSOLOGY, MEDICAL registries, HEMORRHAGE, CHANNEL coding
Abstract

Purpose: The majority of bleeding diagnoses in the Danish National Patient Registry have not been validated despite extensive use in epidemiological research. Therefore, we examined the positive predictive value (PPV) of non-traumatic bleeding diagnoses in the Danish National Patient Registry. Study Design: Population-based validation study. Patients and Methods: Based on a manual review of electronic medical records, we estimated the PPV of diagnostic coding (International Classification of Diseases, Tenth Revision (ICD‐10)) for non-traumatic bleeding for all patients ≥ 65 years of age with any hospital contact in the North Denmark Region during March–December 2019 as registered in the Danish National Patient Registry. We calculated PPVs and associated 95% confidence intervals (CI) for non-traumatic bleeding diagnoses overall and stratified according to primary or secondary diagnosis, and according to major anatomical sites. Results: A total of 907 electronic medical records were available for review. The population mean age was 79.33 years (standard deviation (SD)=7.73) and 57.6% were males. Primary bleeding diagnoses accounted for 766 of the records and 141 were secondary bleeding diagnoses. The overall PPV for bleeding diagnoses was 94.0% (95% CI: 92.3– 95.4). The PPV was 98.7% (95% CI: 97.6– 99.3) for the primary diagnoses and 68.8% (95% CI: 60.7– 75.9) for the secondary diagnoses. When stratified according to subgroups of major anatomical sites, the PPVs ranged between 94.1% and 100% for the primary diagnoses, and between 53.8% and 100% for secondary diagnoses. Conclusion: The overall validity of non-traumatic bleeding diagnoses in the Danish National Patient Registry is high and considered acceptable for epidemiological research. However, PPVs were substantially higher for primary than for secondary diagnosis. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

22. The Electrocardiographic P Terminal Force in Lead V1, Its Components and the Association with Stroke and Atrial Fibrillation or Flutter.

Author

Wolder, Lecia Dixen, Graff, Claus, Baadsgaard, Kirstine H., Langgaard, Monica Lykke, Polcwiartek, Christoffer, Ji-Young Lee, Christina, Skov, Morten Wagner, Torp-Pedersen, Christian, Friedman, Daniel J., Atwater, Brett, Overvad, Thure Filskov, Nielsen, Jonas Bille, Hansen, Steen Moeller, Sogaard, Peter, and Kragholm, Kristian H.

Abstract

Background: ECG marker P Terminal Force V1 (PTFV1) is generally perceived as a marker of left atrial pathology and has been associated with atrial fibrillation or flutter (AF).Objective: To determine the association between PTFV1 components (duration and amplitude) and incident AF and stroke/TIA.Methods: We included patients with an ECG recorded in the Copenhagen General Practitioners Laboratory in 2001-2011. PTFV1 of ≥ 4 mV·ms was considered abnormal. Patients with abnormal PTFV1 were stratified into tertiles based on duration (PTDV1) and amplitude (PTAV1) values. Cox regressions adjusted for age, sex and relevant comorbidities were used to investigate associations between abnormal PTFV1 components and AF and stroke/TIA.Results: Of 267,636 patients, 5,803 had AF and 18,176 had stroke/TIA (follow-up time 6.5 years). Abnormal PTFV1 was present in 44,549 (16.7%) subjects and was associated with an increased risk of AF and stroke/TIA. Among patients with abnormal PTFV1, the highest tertile of PTDV1 (78 ms to 97 ms) was associated with the highest risk of AF (hazard ratio (HR) 1.37 (95% CI: 1.23-1.52)) and highest risk of stroke/TIA (HR 1.13 (95% CI: 1.05 -1.20)). For PTAV1, the highest tertile (78 μV to 126 μV) conferred the highest risk of AF and stroke/TIA, with a HR of 1.20 (95% CI: 1.09-1.32) and 1.21 (95% CI:1.14-1.25), respectively.Conclusion: Abnormal PTFV1 was associated with an increased risk of AF and stroke/TIA. Increasing PTDV1 showed a dose-response relationship with the development of AF and stroke/TIA, while the association between PTAV1 and AF was less apparent. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

28. Risk of stroke and bleeding in patients with heart failure and chronic kidney disease: a nationwide cohort study

Author

Melgaard, Line, Overvad, Thure Filskov, Skjøth, Flemming, Christensen, Jeppe Hagstrup, Larsen, Torben Bjerregaard, and Lip, Gregory Y H

Subjects
Male, Time Factors, Denmark, Heart failure, Hemorrhage, Comorbidity, urologic and male genital diseases, Original Research Articles, Chronic kidney disease, Cause of Death, Humans, Original Research Article, Registries, Mortality, Renal Insufficiency, Chronic, Aged, Retrospective Studies, Incidence, Bleeding, Middle Aged, female genital diseases and pregnancy complications, Stroke, Renal Replacement Therapy, Survival Rate, Population Surveillance, Female, Follow-Up Studies
Abstract

AIMS: The aim of this study was to assess the prognostic value of chronic kidney disease (CKD) in relation to ischaemic stroke, intracranial haemorrhage, major bleeding, and all-cause death in heart failure patients without atrial fibrillation.METHODS AND RESULTS: In this observational cohort study, heart failure patients without atrial fibrillation were identified using Danish nationwide registries. Risk of stroke, major haemorrhage, and death were calculated after 1 and 5 years to compare patients with and without CKD, ±dialysis [dialysis: CKD with renal replacement therapy (CKD-RRT); no dialysis: CKD-no RRT]. A total of 43 199 heart failure patients were included, among which 0.8% had CKD-RRT and 5.9% had CKD-no RRT. When compared with heart failure patients without CKD, both CKD-RRT and CKD-no RRT were associated with a higher 5 year rate of major bleeding (CKD-RRT: adjusted hazard ratio (aHR): 2.91, 95% confidence interval (CI): 2.29 to 3.70; CKD-no RRT: aHR: 1.28, 95% CI: 1.13 to 1.45) and all-cause death (CKD-RRT: aHR: 2.40, 95% CI: 2.07 to 2.77; CKD-no RRT: aHR: 1.63, 95% CI: 1.55 to 1.73). For the endpoints of ischaemic stroke and intracranial bleeding, only CKD-no RRT was associated with significantly higher 5 year rates (ischaemic stroke: aHR: 1.31, 95% CI: 1.13 to 1.52; intracranial haemorrhage: aHR: 1.66, 95% CI: 1.04 to 2.65).CONCLUSIONS: Compared with patients without CKD, among incident heart failure patients without atrial fibrillation, CKD both with and without dialysis was associated with a higher rate of major bleeding and all-cause death. Only CKD-no RRT was associated with a higher rate of ischaemic stroke and intracranial bleeding.

Published
2018

39. Response by Overvad et al to Letter Regarding Article, 'Female Sex Is a Risk Modifier Rather Than a Risk Factor for Stroke in Atrial Fibrillation:Should We Use a CHA 2DS 2-VA Score Rather Than CHA 2DS 2-VASc?'

Author

Overvad, Thure Filskov, Larsen, Torben Bjerregaard, and Nielsen, Peter Brønnum

Abstract

BACKGROUND: Stroke risk in atrial fibrillation is assessed by using the CHA2DS2-VASc score. Sex category (Sc, ie, female sex) confers 1 point on CHA2DS2-VASc. We hypothesized that female sex is a stroke risk modifier, rather than an overall risk factor, when added to a CHA2DS2-VA (sex-independent thromboembolism risk) score scale.METHODS: Using 3 nationwide registries, we identified patients with incident nonvalvular atrial fibrillation from January 1, 1997, through December 31, 2015. Patients receiving oral anticoagulant treatment at baseline were excluded, and person-time was censored at the time of treatment initiation (if any). CHA2DS2-VA scores were calculated for men and women, and were followed for up to 1 year in the Danish National Patient Registry. The primary outcome was a primary hospital code for ischemic stroke or systemic embolism (thromboembolism). We calculated crude event rates for risk strata as events per 100 person-years. For quantifying absolute risk of stroke, we calculated risks based on the pseudovalue method. Female sex as a prognostic factor was investigated by inclusion as an interaction term on the CHA2DS2-VA score to calculate the thromboembolic risk ratio for different score points.RESULTS: A total of 239 671 patients with atrial fibrillation (48.7% women) contributed to the analyses. The mean ages for women and men were 76.6 years and 70.3 years, respectively; the mean CHA2DS2-VA scores were 2.7 for women and 2.3 for men. The overall 1-year thromboembolic rate per 100 person-years for women was 7.3 and 5.7 for men. The 1-year absolute risk of thromboembolism was 0.5% among men and women with a CHA2DS2-VA score of 0 and increased up to >7% among very comorbid patients (score >5). The risk ratio (male as reference) across points >1 indicated that women exhibit a higher stroke risk. The interaction was statistically significant (PCONCLUSIONS: Female sex is a risk modifier for stroke in patients with atrial fibrillation. Initial decisions on oral anticoagulant treatment could be guided by a CHA2DS2-VA score (ie, excluding the sex category criterion), but the Sc risk component modifies and accentuates stroke risk in women who would have been eligible for oral anticoagulant treatment on the basis of ≥2 additional stroke risk factors.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results